Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network

Blood (2024) 144 (Supplement 1): 4535.

https://doi.org/10.1182/blood-2024-202477

Published: 2024

Journal Articles

The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

Blood (2023) 142 (Supplement 1): 3168.

https://doi.org/10.1182/blood-2023-182981

Published: 2023

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase Showing Clinical Resistance to Frontline Treatment with Second Generation Tyrosine Kinase Inhibitors. an Italian Prospective Study from the CML Campus

Blood (2023) 142 (Supplement 1): 6363.

https://doi.org/10.1182/blood-2023-188523

Published: 2023

Journal Articles

Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors

Blood (2019) 134 (Supplement_1): 496.

https://doi.org/10.1182/blood-2019-127514

Published: 2019

Journal Articles

What's Next in CML - a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening

Simona Soverini, PhD, Luana Bavaro, Caterina De Benedittis, PhD, Margherita Martelli, Stefania Stella, PhD, Paolo Vigneri, MD PhD, Alessandra Iurlo, MD PhD, Nicola Orofino, MD, Simona Sica, MD, Federica Sorà, MD, Sara Galimberti, PhD MD, Claudia Baratè, MD PhD, Francesco Albano, MD, Antonella Russo Rossi, MD, Fabio Ciceri, MD, Francesca Lunghi, MD, Fausto Castagnetti, MD, Gabriele Gugliotta, MD PhD, Gianantonio Rosti, MD, Elena Tenti, PhD, Fabio Stagno, MD PhD, Elisabetta Novella, PhD, Eros Di Bona, MD, Massimiliano Bonifacio, MD, Elisabetta Abruzzese, MD PhD, Marzia Salvucci, MD, Mariella D'Adda, MD, Rosaria Sancetta, MD, Elisabetta Calistri, MD, Monica Bocchia, Isabella Capodanno, MD, Giuseppina Spinosa, MD, Maria Antonella Laginestra, PhD, Santa Errichiello, PhD, Anna Serra, Dr, Francesca Carnuccio, Dr, Sabrina Coluzzi, PhD, Mario Annunziata, MD, Caterina Musolino, MD, Fabrizio Pane, MD, Giuseppe Saglio, MD PhD, Michele Baccarani, MD, Michele Cavo, MD, Giovanni Martinelli, MD

Blood (2017) 130 (Supplement 1): 248.

https://doi.org/10.1182/blood.V130.Suppl_1.248.248

Published: 2017

Journal Articles

The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy

Simona Soverini, Caterina De Benedittis, Stefania Stella, Anna Serra, Francesca Carnuccio, Santa Errichiello, PhD, Luana Bavaro, Fausto Castagnetti, MD, Alessandra Iurlo, MD, Nicola Orofino, MD, Federica Sorà, Simona Sica, Sara Galimberti, MD PhD, Claudia Baratè, Federica Mottadelli, Margherita Martelli, Elisabetta Novella, Eros Di Bona, MD, Giorgina Specchia, Francesco Albano, Elisabetta Abruzzese, MD, Fabio Ciceri, MD, Francesca Lunghi, MD, Carmen Fava, MD, Giovanna Rege Cambrin, MD, Luigia Luciano, Massimo Breccia, MD, Clementina Caracciolo, MD, Marco Santoro, Francesco Di Raimondo, MD, Gabriele Gugliotta, Cristina Papayannidis, MD PhD, Giovanni Cazzaniga, Manuela Mancini, Rosaria Sancetta, Renato Bassan, Caterina Musolino, MD, Giuseppina Spinosa, Silvana Franca Capalbo, Mario Annunziata, MD, Michele Cavo, MD, Gianantonio Rosti, Michele Baccarani, Paolo Vigneri, Giuseppe Saglio, MD, Fabrizio Pane, Giovanni Martinelli

Blood (2016) 128 (22): 3097.

https://doi.org/10.1182/blood.V128.22.3097.3097

Published: 2016

Journal Articles

Efficacy and Safety of Yttrium-90 Ibritumomab Tiuxetan in Older Patients with Indolent Non-Hodgkin Lymphoma.

Silvana Capalbo, Gaetano Palumbo, Matteo Dell'Olio, Maria Grazia Franzese, Attilio Guarini, Nicola Di Renzo, Giuseppina Spinosa, Angela Lapietra, Elsa Pennese V, Nicola Cascavilla, MD

Blood (2009) 114 (22): 4795.

https://doi.org/10.1182/blood.V114.22.4795.4795

Published: 2009

Journal Articles

Downregulation of Receptor Activator of Nuclear Factor kB Ligand (RANKL) in Chronic Myeloid Leukemia Patients Receiving Imatinib Mesylate Is Dose-Dependent.

Francesco Albano, MD, PhD, Antonella Zagaria, PhD, Luisa Anelli, PhD, Maria Guastadisegni, PhD, Alessandra Pannunzio, PhD, Giuseppina Spinosa, MD, Mariano Rocchi, PhD, Vincenzo Liso, MD, Giorgina Specchia, MD

Blood (2006) 108 (11): 4786.

https://doi.org/10.1182/blood.V108.11.4786.4786

Published: 2006

NARROW

Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network

The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase Showing Clinical Resistance to Frontline Treatment with Second Generation Tyrosine Kinase Inhibitors. an Italian Prospective Study from the CML Campus

Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors

What's Next in CML - a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening

The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy

Efficacy and Safety of Yttrium-90 Ibritumomab Tiuxetan in Older Patients with Indolent Non-Hodgkin Lymphoma.

Downregulation of Receptor Activator of Nuclear Factor kB Ligand (RANKL) in Chronic Myeloid Leukemia Patients Receiving Imatinib Mesylate Is Dose-Dependent.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only